Optum
The Director of the Malignant Hematology Program will be responsible for providing strategic direction and leadership across our comprehensive portfolio of hematologic malignancy programs. The successful candidate will oversee clinical operations for 13 disease-focused subspecialty programs, ensure excellence in multidisciplinary patient care, and spearhead research initiatives that advance the field of malignant hematology. This role presents an exceptional opportunity to build upon our robust clinical and research infrastructure, collaborating with faculty and university leaders to support our integrated academic, research, and clinical missions.
Requirements include: 1. MD, DO, or equivalent degree with BC in Hem/Onc, with demonstrated expertise across multiple hematologic malignancies. 2. 5+ years of experience leading clinical, translational, and/or basic research programs in malignant hematology, along with an independent, extramurally funded research program (e.g., NIH R01, cooperative group leadership, or industry-sponsored investigational studies). 3. Demonstrate substantial academic productivity with 5+ years of peer-reviewed publications in hematologic malignancies, along with evidence of successful grant acquisition and research program leadership across multiple disease areas. 4. Mid to senior-level faculty experience required, with demonstrated leadership capabilities in academic medicine and program development.
Responsibilities • Lead and manage the comprehensive Malignant Hematology Program encompassing 13 disease-focused subspecialty areas across Indiana University Health's academic medical centers • Collaborate closely with the Hematopoiesis and Hematological Malignancies (HHM) Research Program at IUSCCC to advance translational research initiatives • Work in strategic partnership with the Brown Center for Immunotherapy at Indiana University Melvin and Bren Simon Comprehensive Cancer Center to integrate novel cellular therapy approaches for treatment • Develop and implement strategic initiatives to enhance patient outcomes, expand clinical trial portfolios, and establish disease-specific programs as regional and national referral centers • Provide clinical oversight and academic guidance to multidisciplinary teams, subspecialty faculty, fellows, residents, and advanced practice providers while mentoring junior faculty • Expand the research portfolio with emphasis on investigator-initiated clinical trials, cooperative group studies, and translational research spanning the spectrum of hematologic malignancies • Serve as liaison with external partners, pharmaceutical industry, cooperative groups, and national cancer networks to develop collaborative research opportunities and enhance the program's national prominence • Foster interdisciplinary collaboration among the 13 disease-focused programs to promote knowledge sharing and optimize patient care delivery
Practice Structure • Academic Distribution: 55% Clinical and 45% Academic focus, supporting both patient care excellence and scholarly activities • Clinical Practice: Comprehensive academic practice encompassing clinical care, research, and education across multiple hematologic malignancy subspecialties • Program Scope: Practice comprised of hematology/oncology subspecialists organized into 13 disease-focused programs covering the full spectrum of blood cancers • Practice Locations: University Hospital, Eskenazi Hospital, IU Simon Comprehensive Cancer Center, and affiliated academic medic Community Description
Indianapolis, Indiana
, the 17th largest U.S. city, is a sophisticated city blending charm and culture with a wonderful balance of business and leisure. Residents of this dynamic city enjoy:
Leading educational system and top-ranked universities, paired with a diverse population Vibrant downtown offering arts, theaters, world-class museums, zoo, concerts and memorials Named to
U.S. News & World Report's
2023-2024 list of the best places to live in the United States Top ranked international airport: " Best Airport in North America " twelve consecutive years Ranked by Niche in 2023 as one of the most diverse counties in America, as well as one of the best cities to live in and buy a house in the country Historic neighborhoods with surrounding cultural districts and low cost of living Outdoor recreation includes golfing, boating and unique parks Home of the Colts ( NFL ), Fever ( WNBA ), Pacers ( NBA ), Indians ( MiLB ), Indianapolis 500 ( IndyCar ) and the nation's largest half marathon Close proximity to Chicago, St. Louis ,
Louisville ,
and Cincinnati
Healthcare System/Hospital Description
The
Indiana University Melvin and Bren Simon Cancer Center
is a patient care, research, and educational organization within the
Indiana University School of Medicine
, located on the school's main campus in Indianapolis.
Healthcare providers at IU Health Melvin and Bren Simon Cancer Center not only offer the highest level of patient care but many are engaged in research. As the only National Cancer Institute (NCI)-designated cancer center in the state of Indiana, IU Health Simon Cancer Center's researchers are recognized for meeting rigorous criteria for world-class, state-of-the-art programs in multidisciplinary cancer research. NCI-designated cancer centers put significant resources into developing research programs, faculty and facilities that will lead to better approaches to prevention, diagnosis and treatment of cancer.
In 2022, the IU Health Melvin and Bren Simon Cancer Center was admitted as a member of the National Comprehensive Cancer Network, an alliance of 32 leading cancer centers devoted to patient care, research and education.
The mission is to advance the understanding, prevention and treatment of cancer throughout Indiana and the world with patient-centered care, acceleration of promising science and collaborative educational programs. Research is vigorous, innovative and devoted to taking improved cancer care into the future. In all, more than 200 physicians, nurses, social workers, techologists and researchers are working to develop cures for cancer.
That teamwork leads to clinical breakthroughs, such as turning the cure rate of testicular cancer from 10 percent to nearly 95 percent today, among many others. The benefits to patients are clear: a wide range of innovative treatment options, expert teams of diverse professionals focused on their specific cancer type, and attention to all cancer care needs in one setting. #J-18808-Ljbffr
Requirements include: 1. MD, DO, or equivalent degree with BC in Hem/Onc, with demonstrated expertise across multiple hematologic malignancies. 2. 5+ years of experience leading clinical, translational, and/or basic research programs in malignant hematology, along with an independent, extramurally funded research program (e.g., NIH R01, cooperative group leadership, or industry-sponsored investigational studies). 3. Demonstrate substantial academic productivity with 5+ years of peer-reviewed publications in hematologic malignancies, along with evidence of successful grant acquisition and research program leadership across multiple disease areas. 4. Mid to senior-level faculty experience required, with demonstrated leadership capabilities in academic medicine and program development.
Responsibilities • Lead and manage the comprehensive Malignant Hematology Program encompassing 13 disease-focused subspecialty areas across Indiana University Health's academic medical centers • Collaborate closely with the Hematopoiesis and Hematological Malignancies (HHM) Research Program at IUSCCC to advance translational research initiatives • Work in strategic partnership with the Brown Center for Immunotherapy at Indiana University Melvin and Bren Simon Comprehensive Cancer Center to integrate novel cellular therapy approaches for treatment • Develop and implement strategic initiatives to enhance patient outcomes, expand clinical trial portfolios, and establish disease-specific programs as regional and national referral centers • Provide clinical oversight and academic guidance to multidisciplinary teams, subspecialty faculty, fellows, residents, and advanced practice providers while mentoring junior faculty • Expand the research portfolio with emphasis on investigator-initiated clinical trials, cooperative group studies, and translational research spanning the spectrum of hematologic malignancies • Serve as liaison with external partners, pharmaceutical industry, cooperative groups, and national cancer networks to develop collaborative research opportunities and enhance the program's national prominence • Foster interdisciplinary collaboration among the 13 disease-focused programs to promote knowledge sharing and optimize patient care delivery
Practice Structure • Academic Distribution: 55% Clinical and 45% Academic focus, supporting both patient care excellence and scholarly activities • Clinical Practice: Comprehensive academic practice encompassing clinical care, research, and education across multiple hematologic malignancy subspecialties • Program Scope: Practice comprised of hematology/oncology subspecialists organized into 13 disease-focused programs covering the full spectrum of blood cancers • Practice Locations: University Hospital, Eskenazi Hospital, IU Simon Comprehensive Cancer Center, and affiliated academic medic Community Description
Indianapolis, Indiana
, the 17th largest U.S. city, is a sophisticated city blending charm and culture with a wonderful balance of business and leisure. Residents of this dynamic city enjoy:
Leading educational system and top-ranked universities, paired with a diverse population Vibrant downtown offering arts, theaters, world-class museums, zoo, concerts and memorials Named to
U.S. News & World Report's
2023-2024 list of the best places to live in the United States Top ranked international airport: " Best Airport in North America " twelve consecutive years Ranked by Niche in 2023 as one of the most diverse counties in America, as well as one of the best cities to live in and buy a house in the country Historic neighborhoods with surrounding cultural districts and low cost of living Outdoor recreation includes golfing, boating and unique parks Home of the Colts ( NFL ), Fever ( WNBA ), Pacers ( NBA ), Indians ( MiLB ), Indianapolis 500 ( IndyCar ) and the nation's largest half marathon Close proximity to Chicago, St. Louis ,
Louisville ,
and Cincinnati
Healthcare System/Hospital Description
The
Indiana University Melvin and Bren Simon Cancer Center
is a patient care, research, and educational organization within the
Indiana University School of Medicine
, located on the school's main campus in Indianapolis.
Healthcare providers at IU Health Melvin and Bren Simon Cancer Center not only offer the highest level of patient care but many are engaged in research. As the only National Cancer Institute (NCI)-designated cancer center in the state of Indiana, IU Health Simon Cancer Center's researchers are recognized for meeting rigorous criteria for world-class, state-of-the-art programs in multidisciplinary cancer research. NCI-designated cancer centers put significant resources into developing research programs, faculty and facilities that will lead to better approaches to prevention, diagnosis and treatment of cancer.
In 2022, the IU Health Melvin and Bren Simon Cancer Center was admitted as a member of the National Comprehensive Cancer Network, an alliance of 32 leading cancer centers devoted to patient care, research and education.
The mission is to advance the understanding, prevention and treatment of cancer throughout Indiana and the world with patient-centered care, acceleration of promising science and collaborative educational programs. Research is vigorous, innovative and devoted to taking improved cancer care into the future. In all, more than 200 physicians, nurses, social workers, techologists and researchers are working to develop cures for cancer.
That teamwork leads to clinical breakthroughs, such as turning the cure rate of testicular cancer from 10 percent to nearly 95 percent today, among many others. The benefits to patients are clear: a wide range of innovative treatment options, expert teams of diverse professionals focused on their specific cancer type, and attention to all cancer care needs in one setting. #J-18808-Ljbffr